Patents Assigned to Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Publication number: 20130137867
    Abstract: A novel crystal of antitumor drug erlotinib base and its preparation method are provided in the present invention. A preparation method of erlotinib hydrochloride with high-purity is also provided in the present invention.
    Type: Application
    Filed: August 12, 2011
    Publication date: May 30, 2013
    Applicant: Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Ke Xiang, Min Xu
  • Publication number: 20120172600
    Abstract: A method for preparation of iloperidone is provided which comprises reacting 6-fluoro-3-(4-piperidinyl)-1,2-benzoisoxazole hydrochloride with 1-[4-(3-chloropropoxyl)-3-methoxyphenyl]ethyl ketone in an inorganic alkaline aqueous solution. A crystallization method of iloperidone is also provided which comprises adding seed crystal to the iloperidone solution in ethyl acetate, and then iloperidone crystal is obtained with high purity by controlling the temperature and the stirring speed.
    Type: Application
    Filed: June 21, 2010
    Publication date: July 5, 2012
    Applicant: Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Shiwei Zhou, Feng Jian
  • Publication number: 20120142927
    Abstract: The present invention relates to a method for synthesizing prasugrel, comprising, the following steps: converting o-fluorobenzyl cyclopropyl ketone into ?-cyclopropylcarbonyl-2-fluorobenzyl halide (compound 2) using dibromohydantoinhydantoin as halogenation reagent and acetic acid as solvent, then 2-oxo-4,5,6,7-tetrahydrothieno[3,2-c]pyridine p-toluenesulfonate (compound 4) is obtained with high yield by a concerted catalysis using a phase transfer catalyst and an inorganic salt, then is condensed and acylated to obtain prasugrel as a gum. The present invention also provides a method for purifying prasugrel comprising crystallizing using alcohols as a crystallization solvent to obtain prasugrel crystals with a high purity.
    Type: Application
    Filed: June 23, 2010
    Publication date: June 7, 2012
    Applicant: Zhejiang Huahai Pharmaceutical co., Ltd.
    Inventors: Chuangwei Liu, Qifeng Lu, Changhui Chen
  • Patent number: 8193226
    Abstract: Candesartan cilexetil-containing granules which include a sugar alcohol and a binder and which are produced by granulation with an alcoholic granulating liquid. The granules are suitable for producing tablets in which the candesartan cilexetil is present in a form stabilized with regard to decomposition.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 5, 2012
    Assignees: Zhejiang Huahai Pharmaceutical Co., Ltd., Alfred E. Tiefenbacher GmbH & Co. KG
    Inventors: Qiaomei Wu, Huiyan Gao, Hao Chen, Qiping Yan, Junqing Peng, Gongyun Hu
  • Publication number: 20110046391
    Abstract: The present invention discloses a process for preparing eprosartan mesylate, in which eprosartan is dissolved or suspended in glacial acetic acid, then methanesulfonic acid is added and a solution of eprosartan mesylate in glacial acetic acid is obtained by stirring, a solid of eprosartan mesylate is precipitated by continuously stirring and then obtained by filtration, or a solid of eprosartan mesylate is obtained by concentrating the glacial acetic acid to dry, or a solid of eprosartan mesylate is obtained by adding dropwise an organic ester solvent into the glacial acetic acid under stirring to precipitate a crystal and separate the crystal.
    Type: Application
    Filed: July 20, 2009
    Publication date: February 24, 2011
    Applicant: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
    Inventor: Xiangliang Huang
  • Publication number: 20100267785
    Abstract: Candesartan cilexetil-containing granules which include a sugar alcohol and a binder and which are produced by granulation with an alcoholic granulating liquid. The granules are suitable for producing tablets in which the candesartan cilexetil is present in a form stabilized with regard to decomposition.
    Type: Application
    Filed: October 27, 2008
    Publication date: October 21, 2010
    Applicants: HUAHAI ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., ALFRED E. TIEFENBACHER GMBH & CO. KG
    Inventors: Qiaomei Wu, Huiyan Gao, Hao Chen, Qiping Yan, Junqing Peng, Gongyun Hu
  • Publication number: 20080249311
    Abstract: The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.
    Type: Application
    Filed: September 7, 2006
    Publication date: October 9, 2008
    Applicants: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., CHENGDU ORGANIC CHEMICLAS CO., LTD CHINESE ACADEMY OF SCIENCES
    Inventors: Lixin Wang, Yi Tang, Yi Chen, Fang Tian